Intuitive Surgical
ISRG
$432.01
-3.73%
Intuitive Surgical develops, manufactures, and markets the da Vinci robotic surgical system for minimally invasive procedures, monetizing the installed base through instruments, accessories, and services rather than one-time system sales. With more than 11,000 da Vinci systems placed globally — including over 6,600 in the US — the company operates as the dominant platform incumbent in soft-tissue robotic surgery, a razor-and-blade model that creates high switching costs and a deep competitive moat against emerging entrants such as Medtronic's Hugo. The current investor debate centers on whether Intuitive can sustain high-teens procedure growth as it absorbs the launch costs of its next-generation da Vinci 5 platform, which pressures near-term margins even as system placements and utilization remain robust. Recent Q3 2026 results beat expectations across key metrics on strong placements and procedure volumes, but the stock's sharp mid-year drawdown — triggered in part by management declining to raise full-year guidance after a strong Q2 — reflects a market increasingly focused on the durability of growth and margin trajectory rather than the franchise itself.…
ISRG
Intuitive Surgical
$432.01
Related headlines
Investment Opinion: Should I buy ISRG Today?
Rating: Hold. The core thesis is that Intuitive remains a best-in-class robotic surgery franchise with an 18.5% revenue growth rate, 67.8% gross margins, and a near-monopoly position, but after a 34% three-month rally the shares offer only about 6.2% upside to the $480.13 average analyst target, which does not compensate for the 44% drawdown risk the stock has already demonstrated. The consensus rating of 1.76 (buy) reflects affection for the business more than enthusiasm for the current price.
The supporting evidence is strong on quality: revenue grew 18.54% YoY to $2.892 billion, operating margin expanded to 33.60% from 25.65% in Q1 2025, diluted EPS rose 30% to $2.35, and trailing free cash flow of $3.223 billion is generated with essentially no debt (D/E of 0.017). The forward PE of 36.4x is roughly half the trailing 70.8x, implying the market expects EPS to nearly double toward the $17.98 consensus — a demanding but achievable bar if procedure growth holds. Against a medtech sector that typically trades at 20–30x earnings, the premium is justified by superior fundamentals but leaves no cushion.
The biggest risks that could invalidate the thesis are a deceleration in procedure growth below the mid-teens, persistent da Vinci 5 launch costs keeping gross margin below 68%, and share gains by Medtronic's Hugo. This Hold would upgrade to Buy if the stock pulls back toward $400 (roughly 22x forward earnings) or if management raises guidance and demonstrates margin recovery above 35% operating margin; it would downgrade to Sell if revenue growth decelerates below 12% or if gross margin falls below 65%. On valuation, the stock is fairly valued to modestly expensive relative to its own history — the PE has compressed from 73.8x in Q2 2025 to 42.9x in Q2 2026 — but remains at a steep premium to peers, so the verdict is fairly valued for the quality, not cheap.
Sign up to view all
ISRG 12-Month Price Forecast
The forward view is balanced: the franchise is executing well with 18.5% revenue growth, expanding margins, and pristine cash generation, but the 34% three-month rally has already priced in much of the recovery, leaving just 6.2% upside to consensus. The forward PE of 36.4x is reasonable only if EPS nearly doubles toward $17.98, making procedure growth and da Vinci 5 adoption the swing factors. The wide $324–$685 target range with tight EPS estimates tells us the debate is about the multiple, not the fundamentals. I would upgrade to bullish if management raises guidance and demonstrates operating margin above 35%, and downgrade to bearish if procedure growth falls below 15% or gross margin drops under 65%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $482.63 and implied upside of +11.7% versus the current price.
Average Target
$482.63
0 analysts
Implied Upside
+11.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
Coverage is deep and constructive: 30 analysts follow Intuitive with a consensus recommendation of "buy" (mean rating of 1.76 on a 1–5 scale where 1 is strong buy), and the average target price of $480.13 implies roughly +6.2% upside from the current $452.29. The consensus leans bullish but with tempered enthusiasm — the modest implied upside reflects how much of the recovery has already been priced in after the 34% three-month rally, and the recent ratings flow is mixed: Oppenheimer upgraded to Outperform from Perform in August and BTIG reiterated Buy in September, but HSBC downgraded to Hold from Buy in late July, and the July 17 cluster of reiterations (RBC, Raymond James, Piper Sandler, Wells Fargo, JP Morgan, TD Cowen all maintaining bullish ratings; Mizuho Neutral) shows conviction held through the drawdown without aggressive target raises.
The target range of $324 to $685 is exceptionally wide — a spread of $361, or roughly 80% of the current price — signaling genuine disagreement about the growth trajectory. The high target of $685 implies multiple expansion back toward prior peak valuations and assumes da Vinci 5 adoption accelerates procedure growth while margins recover toward the mid-30s; the low target of $324, essentially at the 52-week low, prices in margin compression from launch costs, competitive pressure from Medtronic's Hugo and other entrants, and a growth slowdown toward the mid-teens. Consensus EPS estimates of $17.98 (range $17.13–$18.59) and revenue of $19.16 billion (range $18.47–$19.66 billion) are relatively tight, suggesting the disagreement is about the multiple rather than the fundamentals — a wide price-target spread paired with tight earnings estimates typically means the market is debating what growth is worth paying for, not whether growth exists.
Bulls vs Bears: ISRG Investment Factors
The bull case rests on a genuinely dominant franchise: 18.5% revenue growth, 67.8% gross margins, 33.6% operating margins, a 0.017 debt ratio, and $3.2 billion of trailing free cash flow, all powered by a recurring instrument model tied to procedure volumes. The bear case is almost entirely about price and expectations: at 20.1x sales and a PEG of 3.17, the stock has already given back 44% from its peak, and management's refusal to raise guidance after a strong Q2 shows how little tolerance the market has for anything short of flawless execution. On balance the evidence currently favors the bulls on fundamentals but the bears on near-term risk/reward — the 34% three-month rally has already captured much of the recovery, leaving only 6.2% upside to the average analyst target. The single most important tension is whether da Vinci 5 adoption accelerates procedure growth enough to justify the forward multiple while margins recover toward the mid-30s; if that happens the stock re-rates toward $600, and if it stalls the multiple compresses toward the $324 low.
Bullish
- Revenue reaccelerating at 18.5% YoY: Q2 2026 revenue of $2.892 billion grew 18.54% year-over-year, extending a clear multi-quarter uptrend from $2.253 billion in Q1 2025. The recurring instruments and accessories line contributed $1.735 billion of that total, meaning growth is driven by procedure volumes rather than lumpy hospital capex.
- Best-in-class margins still expanding: Gross margin of 67.78% and operating margin of 33.60% in Q2 2026 are elite for medtech, and operating margin has climbed from 25.65% in Q1 2025 and 30.47% in Q4 2025. Diluted EPS rose 30% to $2.35 from $1.81 a year earlier, showing operating leverage is kicking in as da Vinci 5 launch costs are absorbed.
- Pristine balance sheet, self-funded growth: Debt-to-equity of just 0.017 and a current ratio of 4.87 mean essentially zero balance-sheet risk. The company generated $3.223 billion in trailing free cash flow and returned $1.44 billion via buybacks across Q1 and Q2 2026 while still growing cash to $2.818 billion.
- Forward PE roughly half trailing multiple: At 70.8x trailing but 36.4x forward earnings, the market is pricing a near-doubling of EPS toward the $17.98 consensus. That 49% compression means investors are paying a far more reasonable multiple for next year's earnings than for the trailing figure, leaving room for the stock to re-rate if growth delivers.
Bearish
- Severe relative underperformance versus market: The stock is down 17.96% over one year and 19.52% YTD against the S&P 500's +13.13% and +11.45%, producing relative strength of -31.09% and -30.97%. A 44% maximum drawdown shows how violently the market de-rated the shares when growth guidance disappointed.
- Valuation still rich on every metric: Even after the de-rating, the stock trades at 20.1x sales, 11.3x book, 49.9x EV/EBITDA, and a PEG of 3.17 — multiples that leave little room for error. The July guidance disappointment that triggered the drawdown is direct evidence of how quickly premium multiples compress on modest news.
- Guidance discipline signals slowing growth: Management declined to raise full-year guidance after a strong Q2, which the market read as a signal of slower growth ahead and drove the July selloff. With the stock priced for near-doubling of earnings, any deceleration toward mid-teens procedure growth would pressure the forward multiple.
- da Vinci 5 launch costs pressure near-term margins: The next-generation platform carries launch and ramp costs that weigh on profitability even as placements remain robust. Gross margin of 67.78% in Q2 2026 is below the 68.04% posted in Q4 2024, showing the launch is not margin-neutral in the near term.
ISRG Technical Analysis
Intuitive Surgical is in a recovery phase within a broader one-year downtrend: the stock is down 17.96% over the trailing year and 19.52% year-to-date, a stark contrast to the S&P 500's +13.13% and +11.45% over the same periods, producing relative strength of -31.09% (1Y) and -30.97% (YTD). At $452.29, the shares sit at roughly 45% of the 52-week range of $328.57–$603.88, having recovered meaningfully off the low but still far below the high — a positioning that suggests repair rather than overextension, with the prior high acting as a distant ceiling. The 44% maximum drawdown underscores how violently the stock de-rated during the first half of the year.
Short-term momentum has turned decisively positive and is diverging sharply from the longer-term trend: the stock is up 13.56% over the past month and 34.01% over three months, versus a 1-month SPY decline of 1.02% and a 3-month SPY gain of just 2.85%, yielding relative strength of +14.58% and +31.16% respectively. That 3-month gain of 34% against a 6-month decline of 6.21% confirms the July low near $332 was a capitulation point followed by a V-shaped rebound, and the 1.90% single-day advance on the latest close ($443.85 to $452.29) on volume of roughly 3.0 million shares suggests buyers remain in control. The divergence — strong 1M/3M momentum against a negative 1Y trend — is characteristic of a mean-reversion rally off oversold conditions rather than a confirmed new uptrend, and the stock still needs to reclaim the $500+ zone to validate a trend reversal.
Key technical levels are well defined: support rests at the 52-week low of $328.57, with a secondary shelf around $350–$375 where the stock consolidated in August and September, while resistance sits at the 52-week high of $603.88, with intermediate supply likely near $470–$480 (the April/May breakdown zone). A breakout above $480 would signal the market is re-rating the growth story and open a path toward the highs; a breakdown below $400 would invalidate the recovery and refocus attention on the $328 low. With a beta of 1.463, the stock is roughly 46% more volatile than the market, meaning position sizing should account for amplified drawdowns — the 44% max drawdown is a live example — and a short ratio of 3.1 indicates moderate but not extreme bearish positioning.
Beta
1.46
1.46x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$329-$604
Price range past year
Annual Return
-18.5%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | +6.2% | -0.9% |
| 3m | +22.3% | +1.2% |
| 6m | -5.6% | +4.9% |
| 1y | -18.5% | +11.2% |
| ytd | -23.1% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust and is reaccelerating: Q2 2026 revenue of $2.892 billion grew 18.54% year-over-year, building on a clear multi-quarter uptrend from $2.253 billion in Q1 2025 through $2.505 billion (Q3 2025), $2.866 billion (Q4 2025), $2.771 billion (Q1 2026), and $2.892 billion (Q2 2026). The segment mix shows the razor-and-blade engine working as intended — instruments and accessories contributed $1.735 billion, services $472.4 million, and systems $685.0 million — with recurring instrument revenue dwarfing capital sales and providing high-visibility growth tied to procedure volumes rather than hospital capex cycles. The trajectory implies a roughly $11.5–12 billion annualized run-rate, consistent with consensus revenue estimates of $19.16 billion for the forward year, and supports the case that procedure growth, not system pricing, is the primary value driver.
Profitability is exceptional and margins are expanding: Q2 2026 net income was $818.1 million on a 28.29% net margin, with gross margin of 67.78% (gross profit of $1.960 billion) and operating margin of 33.60% — up from 30.47% operating margin in Q4 2025 and 25.65% in Q1 2025, a clear upward trajectory as da Vinci 5 launch costs are absorbed and operating leverage kicks in. Diluted EPS reached $2.35 in Q2 versus $1.81 a year earlier, a 30% increase, and EBITDA of $1.174 billion represents a 40.6% EBITDA margin. For a medical device manufacturer, gross margins near 68% and operating margins above 33% are best-in-class, reflecting pricing power from a proprietary ecosystem and a consumables mix that carries far higher margins than capital equipment.
Financial health is pristine: debt-to-equity is just 0.017, the current ratio is 4.87, and the company generated $3.223 billion in trailing free cash flow against a $202 billion market cap (FCF yield of roughly 1.6%), with Q2 operating cash flow of $1.061 billion and capex of only $112.6 million. ROE of 16.02% and ROA of 11.85% are solid though flattered by a low asset base, and the company returned capital via $320.3 million of buybacks in Q2 and $1.123 billion in Q1 while still growing cash to $2.818 billion — evidence that growth is fully self-funded with no external financing dependence. The main cash-flow watch item is working capital: inventory rose $248 million and receivables $74.9 million in Q2, consistent with expanding system placements, but the 0.017 debt ratio means balance-sheet risk is essentially nil.
Quarterly Revenue
$2.9B
2026-06
Revenue YoY Growth
+18.5%
YoY Comparison
Gross Margin
67.8%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Because Intuitive is solidly profitable (Q2 net income of $818.1 million), the PE ratio is the appropriate primary metric: the stock trades at 70.8x trailing earnings but only 36.4x forward earnings, a roughly 49% compression that implies the market expects earnings to nearly double — consistent with consensus EPS of $17.98 versus the trailing figure. The gap between trailing and forward multiples is the single most important valuation signal here: investors are paying a steep price for current earnings but a far more reasonable one for next year's, meaning the stock's fate hinges on delivering that growth. Supporting multiples are equally rich — 20.1x sales, 11.3x book, 66.7x cash flow, and 49.9x EV/EBITDA — all characteristic of a premium-quality compounder rather than a value name.
Against the medical instruments and supplies sector, Intuitive trades at a substantial premium: a PE of 70.8x versus a sector that typically commands 20–30x, a PS of 20.1x versus sector norms in the 3–5x range, and an EV/EBITDA of 49.9x versus mid-teens for large-cap medtech peers. That premium is justified by superior fundamentals — 18.5% revenue growth, 67.8% gross margins, 33.6% operating margins, and a near-monopoly position in robotic soft-tissue surgery — but it leaves little room for error, as the 44% drawdown demonstrated when growth guidance disappointed. The PEG ratio of 3.17 suggests investors are paying more than 3x the growth rate, a rich but not unprecedented multiple for a category leader.
Historically, Intuitive's valuation has compressed meaningfully: the PE ratio stood at 42.9x in Q2 2026 versus 63.2x in Q4 2025 and 73.8x in Q2 2025, while the PS ratio fell from 79.8x a year ago to 48.7x in Q2 2026 — the stock is now near the lower end of its own multi-year band even as the absolute multiple remains high. This de-rating reflects both earnings growth catching up to the price and the market's reduced willingness to pay peak multiples, which cuts both ways: it argues the valuation is less stretched than at the 2025 highs, but the historical range itself (PE of 42x–84x over the past several years) shows the stock has rarely been cheap. At 36.4x forward earnings, the current price embeds optimistic but not heroic expectations, making execution on procedure growth the key swing factor.
PE
70.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 43x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are modest but not zero. The balance sheet is fortress-like with debt-to-equity of 0.017 and a current ratio of 4.87, so solvency is not a concern; the real risk is margin trajectory. Gross margin of 67.78% in Q2 2026 sits below the 68.04% recorded in Q4 2024, and da Vinci 5 launch costs are still being absorbed, meaning any further cost overrun or pricing concession could compress the 33.60% operating margin that the valuation depends on. Working capital is also expanding — inventory rose $248 million and receivables $74.9 million in Q2 — consistent with placements but a watch item if procedure growth slows and channel inventory backs up. Finally, revenue concentration in a single platform is total: essentially all $2.892 billion of quarterly revenue flows through the da Vinci ecosystem, so any clinical, regulatory, or safety issue with the platform would hit the entire P&L at once.
Market and competitive risks are the more pressing concern. The stock trades at 20.1x sales and 49.9x EV/EBITDA versus sector norms of 3–5x sales and mid-teens EBITDA, a premium that requires sustained high-teens growth to defend; the 44% maximum drawdown is a live demonstration of how fast that premium can unwind. Beta of 1.463 means the shares are roughly 46% more volatile than the market, amplifying any sector rotation out of high-multiple healthcare compounders. Competition is intensifying — Medtronic's Hugo is gaining traction per recent coverage, and the analyst low target of $324 explicitly prices in competitive erosion. Regulatory and reimbursement changes for robotic surgery, plus hospital capex sensitivity to interest rates, add external pressure that Intuitive cannot control.
In a worst-case scenario, procedure growth decelerates toward the mid-teens, da Vinci 5 launch costs persist longer than expected, and Hugo wins meaningful share in key procedures — a combination that would compress the forward multiple toward the low end of its historical band. The realistic downside is the 52-week low of $328.57, roughly -27% from the current $452.29, which is also essentially the analyst low target of $324 (-28%). A more severe outcome would revisit the full 44% maximum drawdown, implying a price near $253, though that would require a fundamental break in the franchise rather than a mere multiple reset. Investors should size positions for a 25–30% drawdown as the base-case adverse scenario, not a tail event.
FAQ
The most severe risk is multiple compression: at 20.1x sales and a PEG of 3.17, any growth disappointment triggers sharp de-rating, as the 44% maximum drawdown demonstrated. Second is competitive pressure from Medtronic's Hugo, which the $324 analyst low target explicitly prices in. Third is margin risk from da Vinci 5 launch costs — gross margin of 67.78% in Q2 2026 is already below the 68.04% of Q4 2024. Fourth is macro and volatility risk: beta of 1.463 means the stock moves roughly 46% more than the market, amplifying drawdowns during sector rotation out of high-multiple healthcare names.
The base case (50% probability) targets $460–$520, aligned with the $480.13 average analyst target, assuming high-teens revenue growth and margins holding in the low-to-mid 30s. The bull case (25%) targets $600–$685, requiring da Vinci 5 adoption to accelerate procedure growth and operating margin to recover above 35%. The bear case (25%) targets $324–$380, consistent with the 52-week low and analyst low target, if procedure growth decelerates and Hugo gains share. The base case is most likely because consensus EPS estimates are tight ($17.13–$18.59), suggesting the fundamentals are not in dispute — only the multiple is.
The stock is fairly valued to modestly expensive. The trailing PE of 70.8x looks extreme, but the forward PE of 36.4x is roughly half that, implying the market expects EPS to nearly double toward the $17.98 consensus. Against a medtech sector that typically trades at 20–30x earnings and 3–5x sales, the 20.1x sales and 49.9x EV/EBITDA multiples represent a clear premium. Relative to its own history, however, the stock has de-rated — the PE fell from 73.8x in Q2 2025 to 42.9x in Q2 2026 — so it is near the lower end of its multi-year band. The market is paying for sustained high-teens growth and margin recovery, not for a bargain.
From a risk/reward perspective the setup is balanced rather than compelling. The stock offers only about 6.2% upside to the $480.13 average analyst target after a 34% three-month rally, while the downside to the $328.57 52-week low is roughly -27%. The business quality is exceptional — 18.54% revenue growth, 67.78% gross margin, and a 0.017 debt-to-equity ratio — but at 20.1x sales and a PEG of 3.17 the price already reflects much of that quality. It is a good buy for long-term investors who can tolerate a 44% drawdown and want core exposure to robotic surgery, particularly on pullbacks toward $400. It is less attractive for investors seeking near-term upside given the modest target premium.
ISRG is best suited for long-term holding with a minimum horizon of three to five years. The company is a mature growth compounder with no dividend (payout ratio of 0), so returns depend entirely on earnings growth and multiple stability, which requires time to play out. Beta of 1.463 and a 44% maximum drawdown make it unsuitable for short-term traders without tight risk controls, though the current 34% three-month momentum could support tactical positioning. The razor-and-blade model with 11,000+ installed systems provides high revenue visibility, favoring patient capital. Short-term investors should note the stock needs to reclaim $500 to confirm a trend reversal from the one-year downtrend.